Molecular tests must be performed in all suspected cases, and all results—positive, negative, or inconclusive—must be notified to the Health Ministry within 24 hours.
The ministry stated the move should “ensure greater speed in identifying the virus, […] under surveillance since it was first detected in the country, in June 2022.”
The approved clinical trial is a randomized, double-blind phase 3 study, controlled by placebo, aimed at assessing the effectiveness and safety of Ad26.COV2.S in preventing COVID-19 in adults aged 18 and older.